Research progress of ferroptosis pathway and its related molecular ubiquitination modification in liver cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Ferroptosis, a cell death process, shows promise for liver cancer treatment by inducing tumor cell death. Ubiquitination regulates this process, offering new therapeutic strategies for liver cancer.
Area Of Science
- Biochemistry
- Oncology
- Cell Biology
Background
- Ferroptosis is a novel form of programmed cell death.
- It is characterized by iron accumulation and reactive oxygen species (ROS) generation.
- Ferroptosis plays a role in cancer development and shows potential in liver cancer treatment.
Purpose Of The Study
- To review the role of ubiquitination in regulating ferroptosis.
- To explore the impact of ubiquitination on molecules within the ferroptosis pathway.
- To provide insights into novel liver cancer treatment strategies targeting ferroptosis.
Main Methods
- Literature review of current research on ferroptosis and ubiquitination.
- Analysis of molecular mechanisms linking ubiquitination to ferroptosis.
- Examination of studies on liver cancer treatment utilizing ferroptosis.
Main Results
- Ubiquitination, a protein modification, influences protein stability and ferroptosis progression.
- Specific ubiquitination events regulate key molecules in the ferroptosis pathway.
- Targeting ubiquitination offers a potential strategy to induce ferroptosis in liver cancer cells.
Conclusions
- Ubiquitination significantly modulates ferroptosis.
- Understanding ubiquitination's role in ferroptosis provides a new avenue for liver cancer therapy.
- This review highlights the therapeutic potential of targeting ubiquitination-regulated ferroptosis in liver cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...